Skylark Bio, a clinical-stage biotechnology company developing precision genetic medicines, announced the addition of SKY-AS to its pipeline. SKY-AS is an investigational gene therapy designed to deliver a functional copy of the UBE3A gene to neurons in hopes of restoring UBE3A protein expression. This program is advancing through IND-enabling studies.